CML publications

Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:

Clinical papers

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? – Review
Kantarjian H et al. Leukemia, March 2024 (epub ahead of print)
Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia positive clone or variant Philadelphia translocations
Claudiani S et al. Am J Hematol, March 2024 (epub ahead of print) – open access publication
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
Brioli A et al. Leukemia, March 2024 (epub ahead of print) – open access publication
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: Final analysis and novel prognostic factors for treatment-free remission
Mahon FX et al. J Clin Oncol, March 2024 (epub ahead of print)
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study
Smith BD et al. Leuk Res, March 2024 (epub ahead of print)
High efficacy and safety of asciminib in a chronic myeloid leukemia patient with chronic kidney disease following renal transplantation
Uchida Y et al. Intern Med, March 2024 – open access publication
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements
Bonifacio M et al. Blood Cancer J, March 2024 – open access publication
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI Stopping Trial HALF
Zácková D et al. Leukemia, March 2024 (epub ahead of print) – open access publication
The role of molecular or cytogenetic response as a favourable prognostic factor before hematopoietic cell transplantation for chronic myeloid leukemia
Medeiros GRO et al. Transplant Cell Ther, March 2024 (epub ahead of print)
The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia
Haddad FG et al. Am J Hematol, March 2024 (epub ahead of print) – open access publication
A new algorithm integrating molecular response, toxicity, and plasma level measures for ponatinib dose choice in patients affected by chronic myeloid leukemia
Galimberti S et al. Pharmaceutics, March 2024 – open access publication
The cardiovascular event risk associated with tyrosine kinase inhibitors and the lipid profile in patients with chronic myeloid leukemia
Nieves Saez Perdomo, M et al. Hematol Rep, March 2024 – open access publication
Clinical outcomes of patients with lymphoid blast phase of chronic myeloid leukemia treated with CAR T-cell therapy
Liu Y et al. Blood Cancer J, March 2024 – open access publication

Scientific papers

Mutations in myeloid transcription factors and activated signalling genes predict chronic myeloid leukemia outcomes
Perusini MA et al. Blood Adv, March 2024 (epub ahead of print)
Clinical pharmacokinetics and drug-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia: A clinical perspective – Review
Cheng F et al. Crit Rev Oncol Hematol, March 2024

More CML Publications 2023

Clinical Publications	Scientific Publications
March 2024
Patient versus physician perspective in the management of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors Chen H et al. Oncol Ther, March 2024 – open access publication	The potential of circHIPK3 as a biomarker in chronic myeloid leukemia – Review Gomez EW et al. Front Oncol, March 2024 – open access publication
Real-world effectiveness of dasatinib versus imatinib in newly diagnosed patients with chronic myeloid leukemia Klink AJ et al. Clin Lymphoma Myeloma Leuk, March 2024	CFL1 is implicated in chronic myeloid leukemia response during imatinib therapy Yin X et al. J Cancer, March 2024 – open access publication
Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: Implications for therapeutic response and monitoring Omran MM et al. Eur J Clin Pharmacol, March 2024 (epub ahead of print)	The screening of microRNAs in chronic myeloid leukemia: A clinical evaluation Wosniaki DK et al. Int J Mol Sci, March 2024 – open access publication
Analytical performance evaluation of a digital real-time PCR for quantifying major BCR::ABL1 transcripts Lee SJ et al. J Clin Lab Anal, March 2024 (epub ahead of print) – open access publication	The first case of six-way complex translocation of t(4;7;9;22;8;14) in a patient with chronic myeloid leukemia Bi X et al. J Hematol, March 2024 (epub ahead of print)
Identification and surveillance of rare relapse-initiating stem cells during complete remission after stem cell transplantation Dimitriou M et al. Blood, March 2024 – open access publication
February 2024
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANS1::ARC1A) alteration: A case report with insights on the molecular landscape Fontana D et al. Ann Hematol, February 2024 (epub ahead of print)	Integrated gene co-expression network analysis and experimental validation revealed potential targets of human urine extract CDA-II in treating chronic myeloid leukemia Jiang L et al. Genomics, February 2024 (epub ahead of print) – open access publication
Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia Wang L et al. Int J Lab Hematol, February 2024 (epub ahead of print)	Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models Ansari AS et al. J Control Release, February 2024 (epub ahead of print)
Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction Mu H et al. Hematol Transfus Cell Ther, February 2024 (epub ahead of print) – open access publication	AS1041, a novel derivative of marine natural compound Aspergiolide A induces senescence of leukemia cells via oxidative stress-induced DNA damage and BCR-ABL degradation Lu X et al. Biomed Pharmacother, February 2024 – open access publication
HIF2-alpha expression in CML patients receiving hydroxyurea prior to imatinib that achieved major molecular response (MMR) versus in those not achieving MMR Rinaldi I et al. J Blood Med, February 2024 (epub ahead of print) – open access publication	Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib Klaihmon P et al. Sci Rep, February 2024 (epub ahead of print)
Chronic myeloid leukemia 2.2024, NCCN Clinical Practice Guidelines in Oncology Shah NP et al. J Natl Comp Canc Netw, February 2024 – open access publication	The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia - Review El-Tanani M et al. Pathol Res Pract, February 2024 – open access publication
Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis: A Report from the BCR::ABL1 Pathology Group Rivera D et al. Mod Pathol, February 2024 – open access publication	Beyond BCR::ABL1 – The role of genomic analysis in the management of CML Branford S et al. J Natl Comp Canc Netw, February 2024 – open access publication
Chronic myeloid leukemia diagnosed in pregnancy: management and outcomes of 87 patients reported to the European LeukemiaNet International Registry Chelysheva E et al. Leukemia, February 2024 (epub ahead of print)	Leukemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche Dawson A et al. Nat Commun, February 2024 – open access publication
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia Benesova A et al. Am J Hematol, February 2024 (epub ahead of print) – open access publication	Integrated stress response potentiates ponatinib-induced cardiotoxicity Yan G et al. Circ Res, February 2024 (epub ahead of print)
The contemporary role of hematopoietic stem cell transplantation in the management of chronic myeloid leukemia: Is it the same in all settings? Elmakaty I et al. Cancers(Basel), February 2024 – open access publication	Frequencies of BCR::ABL1 transcripts in patients with chronic myeloid leukemia: A Meta analysis Romero-Morales P et al. Genes(Basel), February 2024 – open access publication
Maximising the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: Potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches Lipton JH. Clin Drug Investig, February 2024	Expression of genes potentially involved in loss of response in patients with chronic myeloid leukemia Benegas P et al. Gene, February 2024
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myeloid leukemia patients Alcazar V et al. Br J Haematol, February 2024 (epub ahead of print) – open access publication	State-transition modelling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia Frankhauser DE et al. Leukemia, February 2024 (epub ahead of print) – open access publication
Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: Strategies to optimize success and new directions – Review Réa D et al. Curr Hematol Malig Rep, February 2024 (epub ahead of print)
Male fertility and fatherhood in chronic myeloid leukemia: Current understanding and future perspectives - Review Elsabagh AA et al. Cancers(Basel), February 2024 – open access publication
Stem cell allografting for chronic myeloid leukemia in the tyrosine kinase era: Forgotten but not gone - Review Tang K & Lipton LH. Leuk Lymphoma, February 2024 (epub ahead of print)
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors Hornak T et al. Am J Hematol, February 2024 (epub ahead of print) – open access publication
Navigating the management of chronic phase chronic myeloid leukemia in the era of generic BCR::ABL1 tyrosine kinase inhibitors - Review Haddad FG & Kantarjian H. J Natl Compr Canc Netw, February 2024 – open access publication
January 2024
Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A Case report and literature review Li Y et al. Medicine (Baltimore), January 2024 – open access publication	Circ-SIRT1 upregulated ATG12 to facilitate imatinib resistance in CML through interacting with EIF4A3 Zhang R et al. Gene, January 2024
Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide in chronic myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation from an unrelated or mismatched related donor: A Comparative study from the Chronic Malignancies Working Party of the EBMT (CHWP-EBMT) Ortí G et al. Transplant Cell Ther, January 2024 – open access publication	Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia – Review Sun J et al. Int J Biol Sci, January 2024 – open access publication
Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors Velmaat L and Cortes J. Blood, January 2024 (epub ahead of print)	Role of miRNAs to control the progression of chronic myeloid leukemia by their expression levels Bansal M et al. Med Oncol, January 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials Jabbour E et al. Leukemia, January 2024 (epub ahead of print) – open access publication	Extracellular vesicles in the chronic myeloid leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules - Review Bernardi S et al. Front Oncol, January 2024 – open access publication
Maximizing the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: Potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches Lipton JH. Clin Drug Investig, January 2024 (epub ahead of print)	Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation Boucher L et al. Leuk Res, January 2024 (epub ahead of print)
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to J.P Gale and J. Chen Pfirrmann M et al. Leukemia, January 2024 (epub ahead of print) – open access publication	Identification and validation of hub genes and molecular classifications associated with chronic myeloid leukemia Zhong F et al. Front Oncol, January 2024 – open access publication
Treatment-free remission after a second TKI discontinuation attempt in patients with chronic myeloid leukemia re-treated with Dasatinib – Interim results from the DAstop2 trial Flygt H et al. Leukemia, January 2024 (epub ahead of publication) – open access publication	Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSC) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs Benjamin ESB Cell Signal, January 2024 (epub ahead of print)
Safety and efficacy of asciminib in a chronic myloid leukemia patient with chronic kidney disease: A case report Alshurufa A et al. Case Rep Oncol, January 2024 – open access publication	Multidrug resistance phenotype and its relation to stem cell characteristics in chronic myeloid leukemia Lettnin AP et al. Gene, January 2024
A review of the therapeutic role of bosutinib in chronic myeloid leukemia – Review Kantarjian HM et al. Clin Lymphoma Myeloma Leuk, January 2024	Activating p53 abolishes self-renewal of quiescent leukemic stem cells in residual CML disease Scott MT et al. Nat Commun, January 2024 – open access publication
Safety and efficacy of tyrosine kinase inhibitors in very elderly patients (≥ 75 years) with chronic myeloid leukemia Costa A et al. J Clin Med, January 2024 – open access publication	Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model Imeri J et al. Front Immunol, January 2024 – open access publication
Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript Dereme J et al. Ann Hematol, January 2024 (epub ahead of print)
What do atomic bomb survivors teach us about treatment-free remission in people with chronic myeloid leukemia Radivoyevitch T et al. Leukemia, January 2024 – open access publication
How to individualized therapy after failing milestones in chronic myeloid leukemia: weighting late response and early death from CML against risk of alternative therapy Hehlmann R and Lauseker M. Leukemia, January 2024 (epub ahead of print) – open access publication
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL fusion gene in Ph-positive leukemias Sponseiler I et al. Am J Hematol, January 2024 – open access publication
Patient versus physician perspective in the management of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors Chen H et al. Oncol Ther, March 2024 – open access publication
Real-world effectiveness of dasatinib versus imatinib in newly diagnosed patients with chronic myeloid leukemia Klink AJ et al. Clin Lymphoma Myeloma Leuk, March 2024
Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: Implications for therapeutic response and monitoring Omran MM et al. Eur J Clin Pharmacol, March 2024 (epub ahead of print)
Analytical performance evaluation of a digital real-time PCR for quantifying major BCR::ABL1 transcripts Lee SJ et al. J Clin Lab Anal, March 2024 (epub ahead of print) – open access publication
Identification and surveillance of rare relapse-initiating stem cells during complete remission after stem cell transplantation Dimitriou M et al. Blood, March 2024 – open access publication
December 2023
CML and the WHO: Why? Berman E et al. J Clin Oncol, December 2023 (epub ahead of print)	Precision isolation of circulating leukemia cells in chronic myelogenous leukemia patients using a novel microfluid device and its clinical applications Ouyaung D et al. Cancers(Basel), December 2023 – open access publication
Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with CML Winn AN et al. JAMA Netw Open, December 2023 – open access publication	Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis Wu A et al. Leukemia, December 2023
Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis at initial presentation: a Report from the BCR::ABL1 Pathology Group Rivera D et al. Mod Pathol, December 2023 (epub ahead of print) – open access publication	The SNP rs460089 in the gene promoter of the drug-transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib Machova Polakova K et al. Leukemia, December 2023 (epub ahed of print) – open access publication
Accelerated-phase CML: de novo and transformed Shanmunagathan N and Hughes TP. Hematology Am Soc Hematol Educ Program, December 2023 – open access publication	A review on characterization of BCR-ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes Zenebe B et al. Hematology Review, December 2023 – open access publication
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ≥ 2 tyrosine kinase inhibitors: a systematic literature review Atallah E et al. Ther Adv Hematol, December 2023 – open access publication	C-Myc inhibition intensified the anti-leukemic properties of imatinib in chronic myeloid leukemia cells Zehtabcheh S et al. Mol Biol Rep, December 2023
Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML Working Group) – in French Réa D et al. Bull Cancer, December 2023 (epub ahead of print) – open access publication	The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTor signaling pathway in chronic myeloid leukemia Liu XY et al. Hematology, December 2023 – open access publication
Resistance mutations in CML and how we approach them - Review Soverini S et al. Hematology Am Soc Educ Program, December 2023 – open access publication	Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia Yin L et al. Hematology, December 2023 – open access publication
SOHO State of the art updates and next questions: Chronic myeloid leukemia and pregnancy: Per Aspera ad Astra” - Review Abruzzese E et al. Clin Lymphoma Myeloma Leuk, December 2023 (epub ahead of print)	miR-181a plays a tumor-suppressor role in chronic myeloid leukemia CD34+ cells partially via SERPINE1 Zhang X et al. Cell Mol Life Sci, December 2023 - open access publication
How to improve treatment-remission eligibility in CML? Review Costa A and Breccia M. Br J Haematol, December 2023 (epub ahead of print) – open access publication	Osimertinib covalently binds to CD34 and eliminates progenitor cells Xia L et al. Cancer Res, December 2023 (epub ahead of print)
The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia Liu L et al. Hematology, December 2023 – open access publication	Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells Yang Y et al. Hematology, December 2023 – open access publication
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy, The Surveillance, Epidemiology, and End Results database, 2000-2019 Sasaki K et al. Cancer, December 2023
Sex-specific incidence of hepatitis B virus flares among BCR-ABL tyrosine kinase inhibitor users in Taiwan Wang LY et al. Pharmacoepidemiol Drug Saf, December 2023
Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans Hofmann J et al. Leukemia, December 2023 – open access publication
Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML Kongruang A et al. Hematology, December 2023 – open access publication
An update of the management of advanced phase chronic myeloid leukemia – Review Short NJ et al. Curr Hematol Malig Rep, December 2023
Evaluation of real-world versus clinical trial outcome of tyrosine kinase inhibitor therapy for chronic myeloid leukemic Collins JB et al. J Oncol Pharm Pract, December 2023 (epub ahead of print) – open access publication
Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: Clinical relevance, impact on outcome, preventive measures and treatment strategies – Review Iurlo A et al. Curr Treat Options Oncol, December 2023 (epub ahead of print)
Exploration of treatment-free remission in CML, based on molecular monitoring – Review Zhang Z et al. Cancer Med, December 2023 (epub ahead of print) – open access publication
November 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia Cross NCP et al. Leukemia, November 2023 – open access publication	Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation Huuhtanen J et al. Leukemia, November 2023 (epub ahead of print) – open access publication
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO Study Zambrotta GPM et al. Am J Hematol, November 2023 – open access publication	Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia Shin JE et al. Mol Cancer, November 2023 – open access publication
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: Results from the phase 4 BYOND study Rosti G et al. Leukemia, November 2023 (epub ahead of print) – open access publication	Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment Häselbarth L et al. BMC Cancer, November 2023 – open access publication
Survival with chronic myeloid leukemia after failing milestones Lauseker M et al. Leukemia, November 2023 – open access publication
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia? Kantarjian HM Leukemia, November 2023
The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib and ponatinib Mulas O et al. Ann Hematol, November 2023
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor Park H et al. Ther Adv Hematol, November 2023 – open access publication
Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients Rafiq Mohammed A et al. Gene, November 2023
October 2023
Viral infections and incidence of reactivation in chronic myeloid leukemia patients – Review Aldapt MB et al. Oncology, October 2023 (epub ahead of print)	Transporter-mediated cellular distribution of tyrosine kinase inhibitors as a potential resistance mechanism in chronic myeloid leukemia - Review Verhagen NE et al. Pharmaceutics, October 2023 – open access publication
Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network analysis – Review Zhang S et al. Expert Opin Drug Saf, October 2023 (epub ahead of print)	Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia Han H et al. Biochem Pharmacol, October 2023 (epub ahead of print)
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions Larfors G et al. Eur J Haematol, October 2023 – open access publication	A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells Zhang X et al. Cell Mol Biol Lett, October 2023 – open access publication
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy Khadadah FM et al. Leuk Res, October 2023	AZD-7648, a DNA-PK inhibitor, induces DNA damage, apoptosis, and cell cycle arrest in chronic and acute myeloid leukemia cells Lapa BS et al. Int J Mol, October 2023 – open access publication
Revisiting six established practices in the treatment of chronic myeloid leukemia - Review Kantarjian HM et al. Lancet Haematol, October 2023	Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis Boucher L et al. Int J Mol, October 2023 – open access publication
Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results Gener-Ricos C et al. Clin Lymphoma Myeloma Leuk, October 2023
Spontaneous remission in a patient with chronic myeloid leukemia: A Case Report Alshurufa A et al. Case Rep Oncol, October 2023 – open access publication
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia Efficace F et al. Cancer, October 2023 (epub ahead of print)